

25 February 2016

GlucoControl Product Manufacturing Commences

Distribution to over 6,000 pharmacies to follow in March 2016

Highlights

- The first manufacturing run has commenced for Omniblend Innovation's flagship product, GlucoControl and clinically tested food-grade pre-meal drink for people with type 2 diabetes (T2D)
- Manufacturing is expected to be complete in March 2016
- The product will be distributed by leading national healthcare wholesaler Symbion under its Faulding brand, reaching its network of over 6,000 pharmacies across Australia and New Zealand
- Manufacturing marks the culmination of six years of development and over \$5 million of investment, including a prestigious \$1.35m grant from the Australian Government's specialist business program, AusIndustry
- Signals imminent first wholesale revenue to Omniblend Innovation

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE is acquiring a ~40% holding, subject to certain conditions (see ASX announcement on 17 December 2015).

Omniblend Innovation has advised that the first manufacturing run for Omniblend Innovation's flagship product, GlucoControl, is underway and is expected to be complete in March 2016.

GlucoControl is a patented food-grade pre-meal drink for people with T2D and pre-diabetes. The pre-meal drink has been clinically shown to reduce blood glucose level peaks by 35% after carbohydrate containing meals.

GlucoControl will be distributed by Symbion, a leading national wholesaler of healthcare services and products, under its Faulding brand to its network of over 6,000 pharmacies, including Chemmart and Pharmacy Choice, across Australia and New Zealand from March 2016.

The commencement of GlucoControl manufacturing marks the culmination of six years of development and over \$5 million investment into the product, including a prestigious \$1.35m grant from AusIndustry, the Australian Government's specialist business program delivering grants and support to innovative businesses and individuals.

Commenting on the milestone, Bill Fry Executive Director of EVE Investments said:

"This first manufacturing run of our GlucoControl pre-meal drink for people with T2D and pre-diabetes, represents a significant milestone for Omniblend Innovation, bringing together over six years of development and \$5 million of investment. It is also the start of commercialisation with revenue generation expected to commence as the product hits the shelves in the coming months."

-ENDS-

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au

Justin Kelly
Media & Capital Partners
0408 215 858
justin.kelly@mcpartners.com.au

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au

For personal use only